PHARMACOLOGICAL ACTIVATION OF THE TRKB RECEPTOR AND ITS EFFECT OF BODY WEIGHT

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The aim of this project was to obtain preliminary data on the efficacy of a recombinant human protein that activates the trkB receptor intravenously administer to obese female baboons with insulin resistance, impaired fasting glucose (prediabetes), hyperglycemia and elevated hemoglobin A1c (HbA1c) levels, on weight, body composition, fasting blood glucose levels and other biochemical parameters related to carbohydrate, lipid and fat tissue metabolism. The animals studied were divided into two groups; one treatment (n = 5) and one control group (n = 5). At baseline all animals were assessed for body composition by DEXA, morphometrics (weight, waist circumference), glucose tolerance and had a baseline blood collection for metabolic profiling. The treatment group received a daily IV dose of the test compound (2mg/kg/day) for a period of 6 weeks. During the course of the study all animals were again assessed for body composition, morphometrics, glucose tolerance along with the collection of a blood sample at the end of weeks 3, and 6.